Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

MK-4280A + Pembrolizumab vs. SOC in patients with Colorectal Cancer

A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer

Disease Types: Colon

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05064059?term=A+Phase+3+study+of+MK-4280A&cond=Colorectal+Cancer&draw=2&rank=1